Trial Completed: Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 (NCT02116764)
WHY IT MATTERS
This completed analysis provides real-world evidence comparing bone marrow transplant outcomes to standard care for CGD patients, which can help your doctor recommend the most effective treatment strategy for your specific situation.
Researchers completed a study following 137 patients with Chronic Granulomatous Disease (CGD), a rare immune system disorder. The study compared patients who received a bone marrow transplant (a procedure to replace damaged blood-forming cells) to patients who received standard medical care instead. This research helps doctors understand which treatment approach works best for CGD patients.
NCT ID: NCT02116764 Status: COMPLETED Conditions: Chronic Granulomatous Disease Enrollment: 137 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Summary: This study is a longitudinal and cross-sectional evaluation of patients with Chronic Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation (HCT) for their disease under a variety of protocols used by participating institutions compared to a control non-HCT group receiving standard care. Investigators at multiple centers caring for patients with CGD in North America and 3 centers in Europe will participate. Patients with CGD will have been treated according
ASK YOUR DOCTOR
Ask your CGD specialist if the results from this study (NCT02116764) apply to your treatment plan or if bone marrow transplant might be an option worth discussing.